1. NF-κB
  2. NF-κB
  3. JSH-23

JSH-23 

Cat. No.: HY-13982 Purity: 99.11%
COA Handling Instructions

JSH-23 is an NF-κB inhibitor which inhibits NF-κB transcriptional activity with an IC50 of 7.1 μM in lipopolysaccharide (LPS)-stimulated macrophages RAW 264.7. JSH-23 inhibits nuclear translocation of NF-κB p65 without affecting IκBα degradation.

For research use only. We do not sell to patients.

JSH-23 Chemical Structure

JSH-23 Chemical Structure

CAS No. : 749886-87-1

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
Solid + Solvent
10 mM * 1 mL in DMSO
ready for reconstitution
USD 117 In-stock
Solution
10 mM * 1 mL in DMSO USD 117 In-stock
Solid
5 mg USD 106 In-stock
10 mg USD 150 In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 84 publication(s) in Google Scholar

Top Publications Citing Use of Products

77 Publications Citing Use of MCE JSH-23

WB
RT-PCR

    JSH-23 purchased from MedChemExpress. Usage Cited in: Cell Rep. 2023 Apr 14;42(4):112403.  [Abstract]

    JSH-23 (10 μM; 6 days) significantly inhibits nuclear translocation of NF-kB p65 in SSC cells.

    JSH-23 purchased from MedChemExpress. Usage Cited in: Front Bioeng Biotechnol. 2020 May 8;8:392.  [Abstract]

    Acta2 expression after Signaling inhibitors by q-PCR. For inhibitor treatment, 24 h after seeding, the medium is removed and replaced with the NF-κB inhibitor JSH-23 (50 μM) to block the NF-κB signaling pathways.

    JSH-23 purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2018 Aug 1;428:77-89.  [Abstract]

    Western blots show that the NF-κB inhibitors BAY11-7082, Parthenolide, and JSH-23 cause dramatic time- and dose-dependent reductions in MGMT protein expression in LN18 and T98G glioma cells.

    JSH-23 purchased from MedChemExpress. Usage Cited in: Front Pharmacol. 2018 Jun 21;9:660.  [Abstract]

    By Western blotting, the α-SMA and palladin proteins are determined in cells that are pretreated with NF-κB (JSH-23), Wnt/β-catenin (XAV939), EGFR (erlotinib), p38 MAPK (TAK-715), and Smad3 (SIS3) inhibitors and are followed by TWEAK stimulation.

    JSH-23 purchased from MedChemExpress. Usage Cited in: J Mol Cell Biol. 2019 Jun 1;11(6):496-508.  [Abstract]

    Cytoplasmic LPS-induced GSDMB and GSDMD expression are both significantly attenuated by either JSH-23 or QNZ.

    JSH-23 purchased from MedChemExpress. Usage Cited in: Int J Clin Exp Pathol. 2017;10(6):6544-6551.

    JSH-23 is added into MDA-MB-231 cells with the dose of 0 μmol, 1 μmol, 5 μmol when the cell planking density reaches about 60%. Then samples incubated for 24 h are collected when the cell density reaches about 80% and confirmed by western blot.

    JSH-23 purchased from MedChemExpress. Usage Cited in: PLoS One. 2016 Nov 16;11(11):e0166740.  [Abstract]

    HG-induced apoptosis in neonatal rat cardiomyocytes is mediated by activation of the NF-κB pathway. (A-B). Neonatal rat cardiomyocytes are pretreated with 10–20 μM JSH-23 and exposed to HG for 36 h. Levels of caspase-3 and cleaved caspase-3 and Bax/Bcl-2 ratios are determined by western blotting.

    View All NF-κB Isoform Specific Products:

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    JSH-23 is an NF-κB inhibitor which inhibits NF-κB transcriptional activity with an IC50 of 7.1 μM in lipopolysaccharide (LPS)-stimulated macrophages RAW 264.7. JSH-23 inhibits nuclear translocation of NF-κB p65 without affecting IκBα degradation[1].

    IC50 & Target[1]

    NF-κB

    7.1 μM (IC50, in RAW 264.7 cells)

    In Vitro

    JSH-2 (1-300 μM; 24 hours) at <100 μM does not show significant cytotoxic effects on the RAW 264.7 cells[1].
    Nuclear amount of NF-κB p65 is markedly increased upon exposure to LPS for 1 h. Treatment of JSH-23 (30 μM; 1 hours) to LPS- stimulated RAW 264.7 cells decreases nuclear content of NF-κB p65 in a dose-dependent manner[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Cell Cytotoxicity Assay[1]

    Cell Line: Macrophages RAW 264.7
    Concentration: 1, 3, 10, 30, 100, 300 μM
    Incubation Time: 24 hours
    Result: Did not show significant cytotoxic effects at <100 μM.

    Western Blot Analysis[1]

    Cell Line: Macrophages RAW 264.7 with LPS-stimulated
    Concentration: 30 μM
    Incubation Time: 1 hour
    Result: Decreased nuclear content of NF-κB p65 in a dose-dependent manner, corresponding to 49±4% inhibition at 3 μM, 75±7% at 10 μM and 95±8% at 30 μM.
    In Vivo

    JSH-23 (1 mg/kg, 3 mg/kg; orally administered; daily; for 2 weeks) significantly reverses the nerve conduction and nerve blood flow deficits seen in diabetic rats[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Male Sprague Dawley diabetic rats (250-270 g)[2]
    Dosage: 1 mg/kg, 3 mg/kg
    Administration: Orally administered; daily; for 2 weeks
    Result: Produced significant improvement in motor nerve conduction velocity (MNCV).
    Molecular Weight

    240.34

    Formula

    C16H20N2

    CAS No.
    Appearance

    Solid

    Color

    Pale purple to purple

    SMILES

    NC1=CC(C)=CC=C1NCCCC2=CC=CC=C2

    Shipping

    Room temperature in continental US; may vary elsewhere.

    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 2 years
    -20°C 1 year
    Solvent & Solubility
    In Vitro: 

    DMSO : ≥ 56 mg/mL (233.00 mM)

    *"≥" means soluble, but saturation unknown.

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 4.1608 mL 20.8039 mL 41.6077 mL
    5 mM 0.8322 mL 4.1608 mL 8.3215 mL
    10 mM 0.4161 mL 2.0804 mL 4.1608 mL
    *Please refer to the solubility information to select the appropriate solvent.
    In Vivo:
    • 1.

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (10.40 mM); Clear solution

    • 2.

      Add each solvent one by one:  10% DMSO    90% Corn Oil

      Solubility: ≥ 2.5 mg/mL (10.40 mM); Clear solution

    *All of the co-solvents are available by MedChemExpress (MCE).
    Purity & Documentation
    References
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    JSH-23 Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

     

    Salutation

    Applicant Name *

     

    Email Address *

    Phone Number *

     

    Organization Name *

    Department *

     

    Requested quantity *

    Country or Region *

         

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    JSH-23
    Cat. No.:
    HY-13982
    Quantity:
    MCE Japan Authorized Agent: